Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Carole Belaïdi |
Documentos disponibles escritos por este autor (1)



Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months / Sidney H. Kennedy en European Neuropsychopharmacology, Año 2016 - Vol. 26 - No.2 (Febrero)
[artículo]
inEuropean Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 378-389
Título : Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months Tipo de documento: texto impreso Autores: Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Carole Belaïdi, Autor Fecha de publicación: 2021 Artículo en la página: pp. 378-389 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agomelatina, Depresión, Placebo, Régimen de dosis, Largo plazo Resumen: This randomized placebo-controlled “dose relation study” was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 patients entered the extension period),... Link: ./index.php?lvl=notice_display&id=26620 [artículo] Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months [texto impreso] / Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Carole Belaïdi, Autor . - 2021 . - pp. 378-389.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 378-389
Palabras clave: Agomelatina, Depresión, Placebo, Régimen de dosis, Largo plazo Resumen: This randomized placebo-controlled “dose relation study” was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 patients entered the extension period),... Link: ./index.php?lvl=notice_display&id=26620